LCM
KNTE

Lynx1 Capital Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Lynx1 Capital Management’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,981,106
Closed -$5.27M – 22
2024
Q1 		$5.27M Sell
1,981,106
-15,900
-0.8% -$39.4K 1.36% 11
2023
Q4 		$4.73M Hold
1,997,006
– – 1.86% 9
2023
Q3 		$2.8M Sell
1,997,006
-51,730
-3% -$124K 1.85% 10
2023
Q2 		$6.21M Sell
2,048,736
-165,514
-7% -$638K 4.07% 9
2023
Q1 		$13.8M Buy
2,214,250
+215,833
+11% +$1.32M 11.54% 4
2022
Q4 		$12.2M Buy
1,998,417
+323,740
+19% +$2.64M 10.54% 4
2022
Q3 		$20M Hold
1,674,677
– – 18.05% 3
2022
Q2 		$21.1M Buy
1,674,677
+982,169
+142% +$9.14M 17.99% 3
2022
Q1 		$7.8M Buy
+692,508
New +$7.62M 7.24% 6

Lynx1 Capital Management's KNTE Position: Q2 2024 in Review

Lynx1 Capital Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 1,981,106 shares — an estimated $5.27M sold.

Lynx1 Capital Management first reported a position in KNTE in Q1 2022 and held it in 9 quarters. The position peaked at $21.1M in Q2 2022. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

  • Lynx1 Capital Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Lynx1 Capital Management sold 1,981,106 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $5.27M.
  • Lynx1 Capital Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2022 and held it in 9 quarters.
  • Lynx1 Capital Management's Kinnate Biopharma Inc. Common Stock position peaked at $21.1M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Lynx1 Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.